We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE) (CASTLE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01520155
First Posted: January 27, 2012
Last Update Posted: December 23, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Henrik Fox, Johann Wolfgang Goethe University Hospitals
  Purpose
The key of this prospective study is to identify a potentially increased cardiovascular risk in patients with systemic Lupus erythematodes, with and without renal affection. Three groups of patients will be compared.

Condition
Systemic Lupus Erythematosus

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE): Studie Zur Detektion Des kardiovaskulären Risikos in Patienten Mit Systemischem Lupus Erythematodes

Resource links provided by NLM:


Further study details as provided by Henrik Fox, Johann Wolfgang Goethe University Hospitals:

Primary Outcome Measures:
  • Identification of cardiovascular risk in patients with systemic Lupus Erythematodes [ Time Frame: one year ]
    Identification of cardiovascular risk in patients with systemic Lupus Erythematodes


Biospecimen Retention:   Samples Without DNA
Every participant will provide 20 ml Serum for further laboratory analysis

Enrollment: 90
Study Start Date: December 2011
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Systemic lupus erythematosus with renal affection
30 patients will be investigated suffering from a known systemic lupus erythematosus with renal affection
Systemic lupus erythematosus without renal affection
30 patients will be investigated suffering from a known systemic lupus erythematosus without renal affection
Non-autoimmune kidney disease
Patients with non-systemic, non-autoimmune kidney disease

Detailed Description:
Key of this prospective study is to identify a potentially increased cardiovascular risk in patients with systemic Lupus erythematodes, with and without renal affection. Three group of patients will be compared as followed. First group are patients with known systemic Lupus erythematodes without renal affection, second group are patients with known systemic Lupus erythematodes with renal affection and the third group are patients with a non-autoimmun chronic kidney disease
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with or without systemic Lupus erythematosus
Criteria

Inclusion Criteria:

  • Patients with systemic Lupus erythematosus

Exclusion Criteria:

  • Patients without systemic Lupus erythematosus
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01520155


Locations
Germany
Frankfurt University Academic Medical Center
Frankfurt am Main, Hessen, Germany, 60590
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospital
Investigators
Study Chair: Joachim R Ehrlich, MD Frankfurt University Academic Medical Center
  More Information

Responsible Party: Henrik Fox, Principal Investigator, Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier: NCT01520155     History of Changes
Other Study ID Numbers: sleffm001
First Submitted: December 12, 2011
First Posted: January 27, 2012
Last Update Posted: December 23, 2013
Last Verified: December 2013

Keywords provided by Henrik Fox, Johann Wolfgang Goethe University Hospitals:
lupus erythematosus
cardiovascular risk

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases